{"id":"NCT00769704","sponsor":"BioVex Limited","briefTitle":"Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma","officialTitle":"A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2013-02","completion":"2014-09","firstPosted":"2008-10-09","resultsPosted":"2015-12-17","lastUpdate":"2016-07-13"},"enrollment":437,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"Talimogene laherparepvec","otherNames":["OncoVEX^GM-CSF","IMLYGICâ„¢"]},{"type":"BIOLOGICAL","name":"GM-CSF","otherNames":["Leukine","Sargramostim"]}],"arms":[{"label":"GM-CSF","type":"ACTIVE_COMPARATOR"},{"label":"Talimogene Laherparepvec","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously administered GM-CSF in patients with unresectable Stage IIIb, IIIc and Stage IV melanoma. The efficacy endpoints of the study aim to demonstrate overall clinical benefit for patients treated with talimogene laherparepvec as compared to GM-CSF.","primaryOutcome":{"measure":"Durable Response Rate","timeFrame":"From randomization until the data cut-off date of 21 December 2012; median follow-up time was 20 months.","effectByArm":[{"arm":"GM-CSF","deltaMin":2.1,"sd":null},{"arm":"Talimogene Laherparepvec","deltaMin":16.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":2},"locations":{"siteCount":83,"countries":["United States","Canada","South Africa","United Kingdom"]},"refs":{"pmids":["26014293","31171039","28923101"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":127},"commonTop":["Fatigue","Chills","Pyrexia","Nausea","Influenza like illness"]}}